Pompe Disease Progression Assessment

Evaluates Pompe disease (glycogen storage disease type II) progression using respiratory function (FVC% predicted), muscle strength testing, and walking distance to guide enzyme replacement therapy decisions.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Evaluates Pompe disease (glycogen storage disease type II) progression using respiratory function (FVC% predicted), muscle strength testing, and walking distance to guide enzyme replacement therapy decisions

Each component has a specific meaning:

  • Respiratory function — The respiratory function recorded for the scenario being assessed.
  • Muscle strength testing — The muscle strength testing recorded for the scenario being assessed.
  • Walking distance — The walking distance recorded for the scenario being assessed.

Note: Interpret the pompe progression result against the thresholds and context described above.

How to Use

Enter the respiratory function, muscle strength testing, walking distance for the scenario you are assessing. Evaluates Pompe disease (glycogen storage disease type II) progression using respiratory function (FVC% predicted), muscle strength testing, and walking distance to guide enzyme replacement therapy decisions. Use the pompe progression result to inform your calculation.

Frequently Asked Questions